Abstract: Disclosed is a Cas12 protein, a guide polynucleotide, an inactivated Cas12 mutant, a fusion protein or conjugate including the Cas12 protein, an isolated nucleic acid, a CRISPR-Cas12 system, a vector system, a delivery system, a cell, a pharmaceutical composition, and a kit, and uses thereof.

Abstract: Cas12 protein, guide polynucleotide, inactivated Cas12 mutant, fusion protein or conjugate including the Cas 12 protein, isolated nucleic acid, CRISPR-Cas12 system, vector system, delivery system, cell, pharmaceutical composition, and kit, and the use thereof are provided.

Abstract: Provided are a novel Cas effector protein, a gene editing system, and uses thereof. The Cas effector protein is CasRfg.3 and similar proteins. The CasRfg.3 (also referred to as Ca2) protein of the present disclosure has a relatively shorter amino acid sequence compared to the commonly used SpCas9 protein, allowing it to be easily packaged into small-capacity gene therapy vectors. The CasRfg.3 corresponds to a unique PAM sequence. Additionally, the CasRfg.3 exhibits excellent specificity in targeting and editing nucleic acid sequences, shows good adaptation to temperature variations, and has a wide temperature tolerance range, functioning effectively under high-temperature conditions, such as being capable of cleaving or modifying target nucleic acids at temperatures ranging from 25° C. to 55° C. The novel Cas effector protein of the present disclosure has significant application value in fields like gene therapy.

Abstract: The present invention relates to a CRISPR-Cas13 system and use thereof, and also relates to a Cas13 protein, a fusion protein, and a guide polynucleotide. The Cas13 protein has at least 90% sequence identity compared to SEQ ID NO: 1. The fusion protein comprises the Cas13 protein fused to a protein domain and/or a polypeptide tag. The guide polynucleotide comprises a same-direction repetition sequence and a guide sequence that has been engineered to hybridize with the target RNA. The same-direction repetition sequence has at least 70% sequence identity to any of SEQ ID NOs: 3 and 80-87. The CRISPR-Cas13 system comprises the Cas13 protein that has at least 90% sequence identity to SEQ ID NO: 1, or a coding nucleic acid therefor, and the guide polynucleotide or a coding nucleic acid therefor.

Abstract: Provided are a novel Cas effector protein, a gene editing system, and uses thereof. The Cas effector protein is CasRfg.3 and similar proteins. The CasRfg.3 (also referred to as Ca2) protein of the present disclosure has a relatively shorter amino acid sequence compared to the commonly used SpCas9 protein, allowing it to be easily packaged into small-capacity gene therapy vectors. The CasRfg.3 corresponds to a unique PAM sequence. Additionally, the CasRfg.3 exhibits excellent specificity in targeting and editing nucleic acid sequences, shows good adaptation to temperature variations, and has a wide temperature tolerance range, functioning effectively under high-temperature conditions, such as being capable of cleaving or modifying target nucleic acids at temperatures ranging from 25° C. to 55° C. The novel Cas effector protein of the present disclosure has significant application value in fields like gene therapy.

Abstract: The present invention relates to a CRISPR-Cas13 system and use thereof, and also relates to a Cas13 protein, a fusion protein, and a guide polynucleotide. The Cas13 protein has at least 90% sequence identity compared to SEQ ID NO: 1. The fusion protein comprises the Cas13 protein fused to a protein domain and/or a polypeptide tag. The guide polynucleotide comprises a same-direction repetition sequence and a guide sequence that has been engineered to hybridize with the target RNA. The same-direction repetition sequence has at least 70% sequence identity to any of SEQ ID NOs: 3 and 80-87. The CRISPR-Cas13 system comprises the Cas13 protein that has at least 90% sequence identity to SEQ ID NO: 1, or a coding nucleic acid therefor, and the guide polynucleotide or a coding nucleic acid therefor.

Abstract: The present invention relates to a CRISPR-Cas13 system and use thereof, and also relates to a Cas13 protein, a fusion protein, and a guide polynucleotide. The Cas13 protein has at least 90% sequence identity compared to SEQ ID NO: 1. The fusion protein comprises the Cas13 protein fused to a protein domain and/or a polypeptide tag. The guide polynucleotide comprises a same-direction repetition sequence and a guide sequence that has been engineered to hybridize with the target RNA. The same-direction repetition sequence has at least 70% sequence identity to any of SEQ ID NOs: 3 and 80-87. The CRISPR-Cas13 system comprises the Cas13 protein that has at least 90% sequence identity to SEQ ID NO: 1, or a coding nucleic acid therefor, and the guide polynucleotide or a coding nucleic acid therefor.

Abstract: The present disclosure relates to an isolated Cas13 protein and use thereof. The amino acid sequence of the isolated Cas13 protein comprises a sequence having ?50% sequence identity with the sequence as shown in any one of SEQ ID NO: 1-SEQ ID NO: 7, and SEQ ID NO: 60. The Cas13 protein is a Cas13 enzyme with an endonuclease activity, which can be used in a CRISPR/Cas system to achieve targeting and modification of a target nucleic acid, enriching the enzymes and systems available in a CRISPR-C as editing system.